Barclays PLC Takes Position in Kewaunee Scientific Co. (NASDAQ:KEQU)

Barclays PLC purchased a new stake in shares of Kewaunee Scientific Co. (NASDAQ:KEQU) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 3,621 shares of the technology company’s stock, valued at approximately $121,000.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. De Lisle Partners LLP grew its position in Kewaunee Scientific by 36.6% in the 3rd quarter. De Lisle Partners LLP now owns 42,958 shares of the technology company’s stock worth $1,446,000 after purchasing an additional 11,511 shares during the period. Renaissance Technologies LLC grew its position in Kewaunee Scientific by 13.4% in the 2nd quarter. Renaissance Technologies LLC now owns 89,611 shares of the technology company’s stock worth $4,230,000 after purchasing an additional 10,580 shares during the period. State Street Corp bought a new stake in Kewaunee Scientific in the 3rd quarter worth approximately $266,000. Dimensional Fund Advisors LP grew its position in Kewaunee Scientific by 3.6% in the 2nd quarter. Dimensional Fund Advisors LP now owns 177,548 shares of the technology company’s stock worth $8,378,000 after purchasing an additional 6,132 shares during the period. Finally, Heron Bay Capital Management bought a new stake in Kewaunee Scientific in the 2nd quarter worth approximately $252,000. Institutional investors own 32.69% of the company’s stock.

Kewaunee Scientific Trading Up 0.3 %

Shares of KEQU stock opened at $61.28 on Thursday. Kewaunee Scientific Co. has a 1 year low of $27.00 and a 1 year high of $67.20. The firm has a fifty day moving average price of $46.78 and a 200-day moving average price of $44.52. The company has a debt-to-equity ratio of 0.48, a current ratio of 2.53 and a quick ratio of 2.00. The company has a market cap of $176.00 million, a price-to-earnings ratio of 9.71 and a beta of 0.72.

Insider Activity

In related news, CEO Thomas David Hull III sold 2,000 shares of Kewaunee Scientific stock in a transaction on Thursday, December 26th. The shares were sold at an average price of $63.01, for a total transaction of $126,020.00. Following the transaction, the chief executive officer now owns 42,497 shares in the company, valued at approximately $2,677,735.97. The trade was a 4.49 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, VP Elizabeth D. Phillips sold 1,850 shares of Kewaunee Scientific stock in a transaction on Tuesday, December 17th. The shares were sold at an average price of $54.17, for a total transaction of $100,214.50. Following the transaction, the vice president now owns 13,591 shares in the company, valued at approximately $736,224.47. This trade represents a 11.98 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 9,369 shares of company stock valued at $572,751 in the last 90 days. Company insiders own 14.20% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, StockNews.com raised shares of Kewaunee Scientific from a “hold” rating to a “buy” rating in a research report on Wednesday, December 18th.

About Kewaunee Scientific

Kewaunee Scientific Corporation designs, manufactures, and installs laboratory, healthcare, and technical furniture and infrastructure products. The company operates through two segments, Domestic and International. Its products include steel and wood casework, fume hoods, adaptable modular systems, moveable workstations, stand-alone benches, biological safety cabinets, and epoxy resin work surfaces and sinks.